Dossier · competitive bodybuilding

Show Prep

Competitive bodybuilding's final week is the most mythologised and least evidenced part of the sport — a stack of manipulations passed down between competitors with almost no controlled testing behind most of them. This is that stack, taken apart piece by piece: what's actually supported (carbohydrate loading, mostly), what's folklore with a plausible mechanism and no real evidence (most water and sodium manipulation), and what has a documented body count (diuretics, DNP, insulin, synthol, and the cardiovascular toll of long-term steroid use itself). The pattern that emerges — danger and effectiveness moving in opposite directions — is the single most useful thing in the whole document.

Research vintage · Q3 2026

Before anything else

What this is, and the two rules it follows

Limited human dataResearcher, own field

Information and mechanism, never a protocol

Every genuinely dangerous item in this dossier — diuretics, DNP, clenbuterol, insulin — is documented by what it did to a real person in the published medical literature, not by a recommended amount. No dose appears anywhere below for anything unregulated or prescription-only. That is the same rule the Reference Protocol dossier follows for the same reason: a dose without the physician, the monitoring, and the years of context behind it is not information a page can responsibly hand out, and for several of the substances here there is no safe dose to give in the first place.

Age gates almost all of this

Nothing in the danger taxonomy below belongs anywhere near a body that has not finished growing. Anabolic-androgenic steroids, growth hormone, insulin and the diuretic/DNP class all interact with an endocrine and skeletal system that is still under construction in the teens and into the early twenties, and the psychiatric condition covered at the end of this dossier — muscle dysmorphia — is measurably more common in exactly this age group. If you are still growing, the correct version of this page is the peak-week section and nothing past it.

The practices with real supporting evidence — carbohydrate manipulation, a modest sodium taper, a planned refeed — are also the least dangerous ones here. The practices that dominate the folklore and the cautionary tales are the ones with the weakest evidence of working and the strongest evidence of harm. That asymmetry is the whole argument of this dossier, and it is worth remembering it before reading a single case report below.

Part 1

Peak week — what's actually supported

Coordinated manipulation of training, carbohydrate, water and sodium in the days before stepping on stage. Almost universal among competitors; almost entirely untested by controlled research.

Limited human dataResearcher, own field

Carbohydrate manipulation — the one with a real mechanism

Ninety-one percent of a surveyed sample of 81 competitive natural bodybuilders used some form of carbohydrate manipulation before their show — the single most common peak-week practice in the sport. Only 6.2% reported eating their normal diet the week before competing.

Mechanism

Glycogen supercompensation

Exhaustive, glycogen-depleting training followed by a predominantly carbohydrate diet produces measurable glycogen supercompensation — the muscle stores more glycogen, and the water that comes bound to it, than it would from a steady diet. Documented protocols scale the loading phase to bodyweight (large gram-per-kilogram carbohydrate loads over two to three consecutive days) following a depletion phase, with both phases running up to four days and full intramuscular saturation estimated at 36–48 hours after the last depleting session.

This is the one manipulation on this page with genuine physiological grounding — glycogen supercompensation is well established outside bodybuilding entirely, in the endurance-nutrition literature. Its danger is not in the mechanism itself but in what it gets stacked with: extended into genuine under-fuelling, or combined with the diuretic and water-restriction practices below, the same manipulation stops being a controlled carbohydrate swing and becomes part of a much riskier combination.

ContestedResearcher, own field

Water and sodium manipulation — folklore with almost no support

This is the load-bearing finding in the peak-week literature, and it runs directly against what most competitors believe: there is a dearth of evidence supporting the water- and sodium-manipulation practices bodybuilders commonly use, and it is unlikely that these manipulations substantially alter sodium-ion concentrations enough to produce the fluid shift they are intended to cause. The technique competitors fear getting wrong the most is also the one least likely to be doing what it is believed to do.

The historical protocol: load sodium hard for the first three days of peak week, then restrict it completely for the three days before competing.
More recent practitioner guidance moves the other way — hold a normal baseline sodium intake through prep, apply only a gentle taper in the final 48 hours, with an optional small bump on show day itself, on the reasoning that available sodium is what drives glucose co-transport into the cell in the first place.
Aggressive depletion followed by a late reload is specifically reported to trigger an aldosterone rebound — and produce exactly the puffy, water-retained look the manipulation was supposed to prevent. The failure mode of the aggressive version is the opposite of its goal.

Where this stops being merely ineffective and starts being dangerous

Water and sodium manipulation on its own is mostly a wasted effort rather than an acute threat. Combined with the diuretics covered in Part 2 — which is how it is actually run by a large share of competitors — the same manipulation removes the safety margin that would otherwise catch a dangerous electrolyte swing before it became one.

Limited human dataPrimary literature

Post-show refeeding — the danger nobody prepares for because it isn't a drug

The research effort in this sport goes almost entirely into getting lean for the stage. What happens metabolically in the days after is comparatively unstudied, and it carries a real, documented, entirely non-pharmacological danger: refeeding syndrome.

Mechanism

Refeeding syndrome

Severe, prolonged carbohydrate restriction shifts the body toward burning fat and protein for fuel and depletes intracellular phosphate, potassium and magnesium even while blood levels look normal. Reintroducing carbohydrate triggers an insulin surge that drives all three electrolytes rapidly back into cells — and if the reintroduction is fast enough, the extracellular level can crash the same way the intracellular level had been depleted, all at once.

This has produced paralysis in a documented case

A published case report describes a competitive bodybuilder who followed five months of inadequate nourishment before competing, then six days of carbohydrate overload afterward — and developed bilateral lower-limb paralysis alongside hypokalaemia, hypophosphataemia and hypomagnesaemia severe enough to require hospital treatment. A separate scoping review found the evidence base for how physique athletes should refeed after a contest is essentially absent — the sport has studied getting lean far more than it has studied getting back to normal.

A gradual, planned refeed protects against a genuine, documented medical emergency. "I'll eat whatever I want the day after the show" is not a plan; it is the exact pattern in the published case above.

Part 2

The danger taxonomy — what operators used, and why not to

Every entry below follows the same shape: what it is, what it was believed to do, and the documented cost. No doses. What follows is mechanism and consequence.

Limited human dataPrimary literature

Loop and potassium-sparing diuretics

Furosemide and spironolactone are prescription drugs for fluid overload in heart failure and cirrhosis, used off-label in the final 24–48 hours before a show to strip subcutaneous water and sharpen the appearance of vascularity and muscle separation.

Mechanism

Why the two classes make each other worse, not better

Loop diuretics dump both sodium and potassium. Potassium-sparing diuretics retain potassium while dumping sodium and water. Stacking them — or misjudging either alone, especially on top of a week of water restriction — produces electrolyte swings large enough to destabilise the heart's electrical rhythm. Spironolactone's own potassium-sparing action carries a documented risk of severe, sometimes fatal hyperkalaemia; a published case describes ventricular standstill as a direct consequence.

The named cautionary case in the sport

Austrian IFBB professional Andreas Münzer, known for extreme conditioning, died in 1996 of dystrophic multi-organ failure. His competition routine included large amounts of potassium-sparing diuretics on top of years of anabolic steroid use; his autopsy found severely deranged electrolytes and catastrophic liver damage. A primary forensic paper on this specific case could not be located and verified here — treat the attribution to diuretics specifically as press-reported rather than confirmed against a forensic toxicology source. What is independently confirmed in the pharmacology literature, regardless of this one case, is that this drug class used this way is a documented cause of fatal arrhythmia on its own.

Limited human dataPrimary literature

DNP (2,4-dinitrophenol)

An industrial chemical — originally a herbicide and explosives component — repurposed as an extreme fat-loss aid.

Mechanism

Uncoupling — why this one has no real safety margin

DNP uncouples oxidative phosphorylation: the proton gradient that would normally drive ATP synthase instead leaks across the mitochondrial membrane, so the energy from burning fuel is released as heat instead of captured as usable energy. The body compensates by burning through fuel far faster, which is the fat-loss effect — and that effect IS the mechanism of harm. There is no dose that produces meaningful fat loss without meaningful heat generation, because they are the same physical process. That is what makes DNP categorically more dangerous than almost anything else on this page.

Documented in fatal case reports, including in teenagers

A published 2024 case describes a 21-year-old bodybuilder who died after six months of repeated DNP use — tachycardia, rapid breathing and profuse sweating were documented from six months before death, with multi-organ-failure hospitalisation four months before it. A separate published case describes a 17-year-old who died after taking DNP with clenbuterol. Fatal hyperthermia from DNP has occurred at levels users themselves believed were controllable — there is no dose ladder here that leads safely upward.

Limited human dataPrimary literature

Clenbuterol

A beta-2 agonist licensed as a veterinary bronchodilator (and, in some countries, a human asthma drug) at low doses, used off-label for its thermogenic and mildly anti-catabolic effect during a cut.

The gap between therapeutic and misuse dosing is not what protects you

Reported bodybuilding use runs several times higher than therapeutic asthma dosing — but published case reports document cardiac toxicity, including myocardial ischaemia and myocarditis, at doses within the nominal therapeutic range in people without a tolerance built up. The margin bodybuilders believe exists between "therapeutic" and "dangerous" does not reliably hold in the case-report literature. Documented presentations include tachycardia, tremor, hypokalaemia and arrhythmia, and there is no reversal agent — treatment is purely supportive.

Limited human dataPrimary literature

Insulin

A prescription hormone for diabetes, used off-label around training for its anabolic and anti-catabolic signalling, and sometimes near a show for the acute "fullness" the nutrient-partitioning push produces.

The least forgiving margin on this entire page

Insulin's therapeutic and lethal effects are separated by physiology that self-administration without an actual diabetes-management infrastructure has no tooling to catch. A published case describes a 30-year-old male bodybuilder who presented in a coma from severe hypoglycaemia, traced to covert insulin injections he had not disclosed to the treating physicians. Misuse is documented as more prevalent among weightlifters and bodybuilders than among other athlete groups, and the clinical risk profile stated plainly in the literature is prolonged hypoglycaemia, arrhythmia, seizure, coma and death. There is no home test that substitutes for continuous glucose monitoring and rescue glucagon on hand.

Mechanism · animal onlyOperator, verifiable record

Growth hormone, insulin, and the visible abdominal distension

A subset of advanced and professional bodybuilders develop a visibly distended, block-shaped abdomen, colloquially "HGH gut" or Palumboism, after bodybuilder David Palumbo, in whom the look became publicly associated with the condition.

Mechanism

Three things happening at once, not simple bloating

Growth hormone drives organomegaly — real enlargement of internal organs, not just muscle. Exogenous insulin, frequently stacked with GH specifically to maximise nutrient uptake, drives visceral fat accumulation. And GH and insulin together drive hypertrophy of the abdominal wall musculature itself, a genuine muscle-growth response in a different muscle group to the same drugs being taken to grow everything else. The visible result is a compound of larger organs, more visceral fat and a thicker ab wall simultaneously — which is why, unlike ordinary bloating, it does not resolve with a water cut.

The evidence gap here, stated honestly

This mechanistic account is physiologically coherent with what GH and insulin are independently well documented to do, but it was not traced to a specific peer-reviewed paper describing the combined syndrome directly. Treat it as the field's working explanation rather than a confirmed mechanism.

Limited human dataPrimary literature

Synthol and other site-enhancement oils

A mixture of oil, alcohol and lidocaine (branded "Synthol," among other names) injected directly into a specific muscle to create localised size independent of actual training or genetics — most commonly used to bring up arms that are lagging the rest of the physique.

It is not muscle, and it does not reverse

This is not primarily a cardiac-risk category the way the rest of this section is — it is direct tissue damage, extensively documented in the dermatology and plastic-surgery case-report literature: pain, deformity and ulceration at the injection site, nerve damage, oil-filled cysts, muscle fibrosis, pulmonary embolism and pulmonary artery obstruction, infection, and reported cerebrovascular accident. One case documents hypercalcaemia and pulmonary granulomatosis as systemic complications from the injections. Established fibrosis has required surgical removal under general anaesthesia. What synthol produces is oil sitting inside and around fibrotic tissue — not muscle — which is why it does not respond to training, dieting or time, and why undoing it generally means surgery rather than anything reversible on its own.

Limited human dataPrimary literature

Anabolic-androgenic steroids — the chronic condition underneath everything above

Everything above concentrates risk in the final days before a show. Long-term anabolic-androgenic steroid use is the chronic condition that makes every acute manipulation on this page more dangerous — and it carries its own, separately documented, population-level cost.

Mechanism

Measurable structural damage, in people who feel completely well

A study of 140 experienced male weightlifters — 86 with at least two years of cumulative lifetime steroid use, 54 non-users — used echocardiography and coronary CT angiography and found steroid users had relatively reduced left-ventricular systolic function compared to non-users, alongside other structural cardiac differences. This is a structural finding in otherwise-healthy, actively training and competing people — the damage is not confined to overdose cases; it is a documented shift in heart function from long-term use itself, present before anyone notices a symptom.

Finding	Figure
Cohort	20,286 male IFBB athletes, 730 competitions, 2005–2020, ~8.1 years average follow-up
Overall death incidence	81 per 100,000 athlete-years
Leading cause of death	Sudden cardiac death — 38% of identified deaths
Professional vs amateur SCD risk	5-fold higher in professionals
Elite "Open" Mr. Olympia-tier competitors	7% died over the study period; 5% from sudden cardiac death
Autopsy findings	Consistent cardiac enlargement and hypertrophy; steroids found in 3 of 5 toxicology analyses performed

Vecchiato, Ermolao, Da Col, Aghi, Berton, Palermi, Battista, Savino, Drezner, Zorzi, Niebauer & Neunhaeuserer, European Heart Journal, 46(30):3006–3016, 2025.

A five-fold relative risk increase and a documented single-digit-percent absolute sudden-cardiac-death rate at the top competitive tier are not small print. They describe a sport whose most successful practitioners are dying of heart disease in their thirties at a rate that would be treated as a public-health scandal in almost any other context.

Part 3

Muscle dysmorphia — the driver the pharmacology gets blamed for

Nearly everything in Part 2 is a technique someone chose to use. The choice itself has a documented psychiatric substrate the surface-tier content in this space almost never names.

Limited human dataPrimary literature

A specific, diagnosable, treatable condition — not vanity

Muscle dysmorphia ("bigorexia") is a specific form of body dysmorphic disorder: a preoccupation with the belief that one's body is insufficiently large or lean, regardless of actual muscularity. It was first clinically described by Harrison Pope, Katharine Phillips and Roberto Olivardia — Harvard Medical School researchers who remain the field's foundational authorities on the condition.

Population	Reported prevalence
General university-age men	≈1.9–5.9%
Male weightlifters specifically	≈13.6–44%
Competitive athletes vs non-competitive lifters	Higher risk in the competitive group

Ranges as reported across indexed reviews synthesising the primary clinical literature; wide variance reflects differing diagnostic criteria and sampled populations.

The pattern is not a coincidence

The published case report of a fatal DNP intoxication cited in Part 2 names muscle dysmorphia in its own title, alongside the drug use that killed the patient. The psychiatric condition and the pharmacological escalation are frequently the same story told from two different departments of the hospital — the diagnosis in one, the toxicology in the other.

The demand for the techniques in Part 2 is frequently generated by a diagnosable, treatable condition, not by an accurate read of what a competitive physique actually needs. Recognising the preoccupation described above in yourself is better served by a conversation with a clinician than by any protocol on this page — see The Mind for the same standard applied to cognition and connection more broadly.

Referenced in

Show Prep: The Full Case Record

Every mechanism in the danger taxonomy explained down to the level a curious reader could actually follow — what oxidative phosphorylation has to do with DNP, why potassium-sparing and loop diuretics make each other worse, why insulin has the least forgiving margin of anything in the sport, and the full mortality data from the largest cohort study of competitive bodybuilders ever run. Nothing here is a protocol. It's the reference the shorter article didn't have room for.

Danger and Evidence Run in Opposite Directions

The practices with real supporting evidence in competitive bodybuilding's final week — carbohydrate loading, a modest sodium taper, a planned refeed — are also the least dangerous ones. The practices that dominate the cautionary stories — diuretics, DNP, insulin, synthol — have the weakest evidence of working and a documented, population-level body count. Here's the taxonomy, sourced to the published case reports and cohort studies, with the mechanism for each and nothing about how much to take.

Research notes, not medical or financial advice. Every prescription or experimental item named here is named with its mechanism and its risk and without a dose, on purpose — several require physician supervision, several are unregulated, and several are inappropriate for a body that is still developing. Start from your own bloodwork and a doctor, never from someone else’s regimen.

Non invenitur. Fit.